NCT03737812

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 123 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).

Conditions

• Multiple Sclerosis (MS)

Interventions

Type	Name	Description
DRUG	elezanumab	solution for infusion
DRUG	placebo	solution for infusion

Timeline

• Start date: 2019-02-27
• Primary completion: 2021-01-15
• Completion: 2021-08-30
• First posted: 2018-11-13
• Last updated: 2023-12-21
• Results posted: 2023-12-21

Locations

37 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study